Jacob M. Keck

Researcher

UAMS

Also affiliated: Jackson Memorial Hospital (2022); University of Mississippi Medical Center (2022)

Faculty Researcher

5 h-index 8 pubs 100 cited

Research Areas

Biomedical Subjects

Links

Research Group

OverviewAI-generated summary

Jacob M. Keck's research focuses on antimicrobial resistance and the development of new therapeutic strategies. His work has investigated treatment-emergent resistance to cefiderocol in carbapenem-resistant *Acinetobacter baumannii*, linking this resistance to the insertion sequence IS *Aba36* within the siderophore receptor *pirA*. Keck also examines antifungal resistance and the evaluation of antifungal stewardship initiatives, including the use of micafungin. His recent publications explore the challenges and approaches to managing fever in neutropenic patients, the emergence of resistance to new antibiotics, and case series utilizing novel antifungal agents like rezafungin for invasive candidiasis. He has also published on the use of combination therapies, such as aztreonam–avibactam with eravacycline, for complex bacterial infections. Keck's research network includes collaborators such as Ryan K. Dare and Alina Viteri at the University of Arkansas for Medical Sciences.

Metrics

h-index: 5
Publications: 8
Citations: 100

Selected Publications

Beyond β-Lactams: Defining the Role of Eravacycline in Multidrug-Resistant and Metallo-β-Lactamase-Producing Infections (2026)

Antibiotics DOI OpenAlex
Use of Aztreonam–Avibactam with Rapid Eravacycline Step-Down Therapy for a Tibial Septic Non-Union by NDM-Producing Enterobacter cloacae (2025)

Antibiotics 2 citations DOI OpenAlex
“Dusting Off the Cobwebs”: Rethinking How We Use New Antibiotics (2025)

Antibiotics 2 citations DOI OpenAlex
It’s Here, It’s There, There’s Fungi Everywhere: A Case Series Utilizing Rezafungin for Invasive Candidiasis (2025)

Infectious Diseases and Therapy 10 citations DOI OpenAlex
New Agents Are Coming, and So Is the Resistance (2024)

Antibiotics 12 citations DOI OpenAlex
Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence IS Aba36 in the siderophore receptor pirA (2024)

Antimicrobial Agents and Chemotherapy 25 citations DOI OpenAlex
Antifungal resistance, combinations and pipeline: oh my! (2023)

Drugs in Context 18 citations DOI OpenAlex
Evaluation of an Antifungal Stewardship Initiative Targeting Micafungin at an Academic Medical Center (2023)

Antibiotics 3 citations DOI OpenAlex